Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Phase I trial evaluates MVA-BN PRO in castration-resistant prostate cancer

Oct. 21, 2010

ONO-4641 shows safety and tolerability in phase I trial in MS

Oct. 21, 2010

Subanalyses of CLARITY data support benefits of cladribine tablets

Oct. 21, 2010

Zealand Pharma's ZP-2307 shows bone anabolic activity in vivo

Oct. 21, 2010

New antibiotics for multidrug-resistant pathogens in preclinical/clinical evaluation

Oct. 21, 2010

Ocrelizumab reduces disease activity in phase II trial in relapsing-remitting MS

Oct. 20, 2010

DepoVax-based vaccination leads to tumor regression in vivo

Oct. 20, 2010

HIV vaccine ALVAC vCP1521 is safe in infants given birth to by HIV-infected women

Oct. 20, 2010

Snapshots: Studies of new antibiotic CB-182804

Oct. 20, 2010

Cancer vaccine CDX-1401 safe and active in ongoing phase I/II trial

Oct. 20, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
Other news to note for May 1, 2026
BioWorld
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: AC Immune, Aptose, Astrazeneca, Bioreference Health, Cardioline,...